Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Kinetics Medical Advisor Fund Class C (KRXCX)

27.15
Net Asset Value
-1.95%
1 Day
-5.79%
Year-to-Date
Overall Morningstar Rating
Health
Style or Category
No Load
Sales Expenses
2.74%
Expense Ratio
Average
Morningstar Risk Rating™
Investment Objective The investment seeks long-term growth of capital. The fund is a non-diversified fund that invests all of its investable assets in the Medical Portfolio, a series of Kinetics Portfolios Trust. The Portfolio invests at least 80% of its net assets plus any borrowings for investment purposes in common stocks, convertible securities, warrants, and other equity securities having the characteristics of common stocks of U.S. and foreign companies engaged in medical research, pharmaceutical and medical technology industries and related technology industries, with an emphasis toward companies engaged in cancer research and drug development. It is non-diversified.

Performance

1 month+1.27% 3 years+7.28%
3 months+6.43% 5 years+14.63%
1 year+3.58% Since inception+7.99%
Data through --

Peer Comparisonvs. Health

 KRXCXCategory
Performance 5-yr return+14.63%+15.57%
Expense ratio2.74%1.32%
Risk 5 year sharpe ratio0.881.19
Net assets$23.7M$3.2B
Average market cap$59.1B$37.2B
Average P/E25.520.2
Portfolio turnover12%12%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyKinetics
Fund manager & tenureBruce Abel / 16 Years
Minimal initial investment$2,500.00
Minimum IRA investment$2,500.00

Holdings

U.S. stock66.30%
International stock31.34%
Cash2.32%
Fixed income0.03%
Other0.00%
Top 5 Sectors
Portfolio weighting
Healthcare 94.65%
Industrial materials 4.23%
Business service 1.12%
Telecommunication 0.01%
Consumer goods 0.00%
Top 10 Holdings
Portfolio weighting
BMY Bristol-Myers Squibb10.57%
JNJ Johnson & Johnson7.69%
LLY Eli Lilly and Co7.66%
BIIB Biogen6.90%
PFE Pfizer6.85%
NVS Novartis6.28%
SNY Sanofi4.78%
SHPG Shire4.67%
ALKS Alkermes Plc4.57%
GSK GlaxoSmithKline4.52%